Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Immunocore Holdings Plc ADR (NQ: IMCR )

49.77 -0.90 (-1.78%)
Streaming Delayed Price Updated: 10:07 AM EDT, Sep 28, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Immunocore Holdings Plc ADR

< Previous 1 2 3 Next >
Cancer Focused Immunocore Leads The Way In TCR Therapeutics, Positioned For Success: Analyst Says
Needham has initiated coverage on Immunocore Holdings Plc (NASDAQ: IMCR) with a Buy rating and  
Via Benzinga
Analyst Expectations for Immunocore Hldgs's Future
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 13, 2023
Via Benzinga
Where Immunocore Hldgs Stands With Analysts
Via Benzinga
Immunocore Hldgs's Earnings Outlook
Via Benzinga
Where Immunocore Hldgs Stands With Analysts
Via Benzinga
Analyst Ratings for Immunocore Hldgs
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 16, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 17, 2023
Via Benzinga
Expert Ratings for Immunocore Hldgs
Via Benzinga
Recap: Immunocore Hldgs Q1 Earnings
Via Benzinga
Analyst Ratings for Immunocore Hldgs
Via Benzinga
Short Volatility Alert: Immunocore Hldgs
On Friday, shares of Immunocore Hldgs (NASDAQ: IMCR) experienced volatile short activity. After the activity, the stock price went up +3.38% to $54.81. The overall sentiment for IMCR has been Bearish. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 30, 2023
Via Benzinga
Earnings Scheduled For March 1, 2023
Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million. 
Via Benzinga
Preview: Immunocore Holdings's Earnings
Via Benzinga
Immunocore Reveals First Data From HIV Infection Candidate Study
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Biotech's Drug Pipeline Expands From Melanoma To Other Cancers
Immunocore is the IBD Stock of the Day as the biotech company expands its pipeline. Earnings For IMCR stock are due in March. 
Via Investor's Business Daily
3 Pharma Stocks That Will Mint Millionaires
These pharma stocks all have excellent risk-reward ratios and the companies have developed treatments that could easily become blockbusters. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For November 30, 2022
Via Benzinga
Analyst Ratings for Immunocore Hldgs
Via Benzinga
Where Immunocore Hldgs Stands With Analysts
Via Benzinga
7 Analysts Have This to Say About Immunocore Hldgs
Via Benzinga
Where Immunocore Hldgs Stands With Analysts
Immunocore Hldgs (NASDAQ:IMCR) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 16, 2022
Via Benzinga
Procter & Gamble To Jump Over 16%? Here Are 5 Other Price Target Changes For Monday
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  During Monday's session, 50 stocks hit new 52-week highs. 
Via Benzinga
After Bill Gates Dumps Billions In Berkshire To Buy Microsoft, His Quiet Biotech Portfolio Has Made A New Trade
Bill Gates has two portfolios he makes trades from: the Bill & Melinda Gates Foundation and the Bill & Melinda Gates Foundation Trust. 
Via Benzinga
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.